RU2012144555A - Конъюгированный фактор свертывания крови viii - Google Patents
Конъюгированный фактор свертывания крови viii Download PDFInfo
- Publication number
- RU2012144555A RU2012144555A RU2012144555/15A RU2012144555A RU2012144555A RU 2012144555 A RU2012144555 A RU 2012144555A RU 2012144555/15 A RU2012144555/15 A RU 2012144555/15A RU 2012144555 A RU2012144555 A RU 2012144555A RU 2012144555 A RU2012144555 A RU 2012144555A
- Authority
- RU
- Russia
- Prior art keywords
- fviii
- pharmaceutical composition
- conjugate
- bond
- composition according
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims 2
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 18
- 102100026735 Coagulation factor VIII Human genes 0.000 claims abstract 16
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims abstract 16
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 12
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims abstract 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims abstract 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 8
- 125000002947 alkylene group Chemical group 0.000 claims abstract 7
- 239000000203 mixture Substances 0.000 claims abstract 5
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims abstract 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims abstract 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims abstract 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003118 aryl group Chemical group 0.000 claims abstract 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims abstract 4
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 229920000642 polymer Polymers 0.000 claims abstract 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims abstract 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract 3
- 125000004434 sulfur atom Chemical group 0.000 claims abstract 3
- 239000013543 active substance Substances 0.000 claims abstract 2
- 239000002671 adjuvant Substances 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 239000000839 emulsion Substances 0.000 claims abstract 2
- 238000001802 infusion Methods 0.000 claims abstract 2
- 239000007927 intramuscular injection Substances 0.000 claims abstract 2
- 238000010255 intramuscular injection Methods 0.000 claims abstract 2
- 238000001990 intravenous administration Methods 0.000 claims abstract 2
- 125000005647 linker group Chemical group 0.000 claims abstract 2
- 238000007911 parenteral administration Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims abstract 2
- 239000007929 subcutaneous injection Substances 0.000 claims abstract 2
- 238000010254 subcutaneous injection Methods 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- 239000000725 suspension Substances 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 9
- 208000014674 injury Diseases 0.000 claims 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 208000015294 blood coagulation disease Diseases 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 230000001268 conjugating effect Effects 0.000 claims 2
- 208000009429 hemophilia B Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 208000002085 hemarthrosis Diseases 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 208000007106 menorrhagia Diseases 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 150000007944 thiolates Chemical class 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000003827 glycol group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1007357.5A GB201007357D0 (en) | 2010-04-30 | 2010-04-30 | Conjugated factor VIII |
| GB1007357.5 | 2010-04-30 | ||
| PCT/GB2011/000662 WO2011135307A1 (en) | 2010-04-30 | 2011-04-28 | Conjugated blood coagulation factor viii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012144555A true RU2012144555A (ru) | 2014-06-10 |
Family
ID=42289987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012144555/15A RU2012144555A (ru) | 2010-04-30 | 2011-04-28 | Конъюгированный фактор свертывания крови viii |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20130150302A1 (enExample) |
| EP (1) | EP2563402A1 (enExample) |
| JP (1) | JP5870088B2 (enExample) |
| KR (1) | KR20130055619A (enExample) |
| CN (1) | CN102939108A (enExample) |
| AP (1) | AP2012006575A0 (enExample) |
| AU (1) | AU2011247147B2 (enExample) |
| BR (1) | BR112012027590A2 (enExample) |
| CA (1) | CA2797058A1 (enExample) |
| CL (1) | CL2012003039A1 (enExample) |
| CO (1) | CO6660443A2 (enExample) |
| CR (1) | CR20120579A (enExample) |
| EA (1) | EA201290938A1 (enExample) |
| EC (1) | ECSP12012314A (enExample) |
| GB (2) | GB201007357D0 (enExample) |
| IL (1) | IL222566A (enExample) |
| MX (1) | MX2012012683A (enExample) |
| MY (1) | MY160922A (enExample) |
| NI (1) | NI201200160A (enExample) |
| NZ (1) | NZ603939A (enExample) |
| PE (1) | PE20130254A1 (enExample) |
| PH (1) | PH12012502150A1 (enExample) |
| RU (1) | RU2012144555A (enExample) |
| SG (1) | SG184906A1 (enExample) |
| WO (1) | WO2011135307A1 (enExample) |
| ZA (1) | ZA201208989B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2789085C2 (ru) * | 2018-05-18 | 2023-01-30 | Чжэнчжоу Дженсайнсес Инк. | Улучшенный белок слияния fviii и его применение |
| US12440572B2 (en) | 2018-05-18 | 2025-10-14 | Zhengzhou Gensciences Inc. | FVIII fusion protein and use thereof |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5876208B2 (ja) | 2006-12-15 | 2016-03-02 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体 |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| JP5909755B2 (ja) | 2009-07-27 | 2016-04-27 | リポクセン テクノロジーズ リミテッド | 非血液凝固タンパク質の糖ポリシアル酸化 |
| EP3093029A1 (en) | 2009-07-27 | 2016-11-16 | Baxalta GmbH | Blood coagulation protein conjugates |
| SG178141A1 (en) | 2009-07-27 | 2012-03-29 | Baxter Int | Blood coagulation protein conjugates |
| DK2654794T3 (da) | 2010-12-22 | 2020-06-08 | Baxalta GmbH | Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein |
| EA033469B1 (ru) | 2012-04-16 | 2019-10-31 | Cantab Biopharmaceuticals Patents Ltd | Подкожное введение конъюгатов факторов крови с полиэтиленгликолем |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2572733A1 (en) * | 2003-02-26 | 2013-03-27 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| LT1824988T (lt) * | 2004-11-12 | 2017-10-25 | Bayer Healthcare Llc | Nukreipta į užduotą saitą fviii modifikacija |
| PL1835938T3 (pl) * | 2004-12-27 | 2014-01-31 | Baxalta Inc | Koniugaty polimer-czynnik von Willebrandta |
| CA2647314A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| DK2209494T3 (en) | 2007-10-09 | 2016-10-03 | Polytherics Ltd | New conjugated proteins and peptides |
| KR20110016440A (ko) * | 2008-04-24 | 2011-02-17 | 셀틱 파르마 피이지 엘티디. | 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체 |
| CN102099058B (zh) * | 2008-07-21 | 2014-10-22 | 宝力泰锐克斯有限公司 | 用于缀合生物分子的新试剂和方法 |
| GB0912485D0 (en) * | 2009-07-17 | 2009-08-26 | Polytherics Ltd | Improved conjugation method |
-
2010
- 2010-04-30 GB GBGB1007357.5A patent/GB201007357D0/en not_active Ceased
-
2011
- 2011-04-28 MX MX2012012683A patent/MX2012012683A/es not_active Application Discontinuation
- 2011-04-28 PH PH1/2012/502150A patent/PH12012502150A1/en unknown
- 2011-04-28 WO PCT/GB2011/000662 patent/WO2011135307A1/en not_active Ceased
- 2011-04-28 EA EA201290938A patent/EA201290938A1/ru unknown
- 2011-04-28 SG SG2012077087A patent/SG184906A1/en unknown
- 2011-04-28 CN CN2011800218881A patent/CN102939108A/zh active Pending
- 2011-04-28 CA CA2797058A patent/CA2797058A1/en active Pending
- 2011-04-28 NZ NZ603939A patent/NZ603939A/xx not_active IP Right Cessation
- 2011-04-28 AP AP2012006575A patent/AP2012006575A0/xx unknown
- 2011-04-28 MY MYPI2012004710A patent/MY160922A/en unknown
- 2011-04-28 US US13/643,287 patent/US20130150302A1/en not_active Abandoned
- 2011-04-28 BR BR112012027590A patent/BR112012027590A2/pt not_active IP Right Cessation
- 2011-04-28 RU RU2012144555/15A patent/RU2012144555A/ru not_active Application Discontinuation
- 2011-04-28 KR KR1020127031386A patent/KR20130055619A/ko not_active Ceased
- 2011-04-28 PE PE2012002104A patent/PE20130254A1/es not_active Application Discontinuation
- 2011-04-28 GB GB201220667A patent/GB2492935B8/en not_active Expired - Fee Related
- 2011-04-28 EP EP11719040A patent/EP2563402A1/en not_active Withdrawn
- 2011-04-28 AU AU2011247147A patent/AU2011247147B2/en not_active Ceased
- 2011-04-28 JP JP2013506735A patent/JP5870088B2/ja not_active Expired - Fee Related
-
2012
- 2012-10-21 IL IL222566A patent/IL222566A/en not_active IP Right Cessation
- 2012-10-29 NI NI201200160A patent/NI201200160A/es unknown
- 2012-10-29 CL CL2012003039A patent/CL2012003039A1/es unknown
- 2012-11-14 CR CR20120579A patent/CR20120579A/es unknown
- 2012-11-28 EC ECSP12012314 patent/ECSP12012314A/es unknown
- 2012-11-28 ZA ZA2012/08989A patent/ZA201208989B/en unknown
- 2012-11-29 CO CO12216949A patent/CO6660443A2/es unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2789085C2 (ru) * | 2018-05-18 | 2023-01-30 | Чжэнчжоу Дженсайнсес Инк. | Улучшенный белок слияния fviii и его применение |
| US12440572B2 (en) | 2018-05-18 | 2025-10-14 | Zhengzhou Gensciences Inc. | FVIII fusion protein and use thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012144555A (ru) | Конъюгированный фактор свертывания крови viii | |
| RU2012144554A (ru) | КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa | |
| JP2013525414A5 (enExample) | ||
| RU2010147813A (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
| JP2011519833A5 (enExample) | ||
| EP1792927B1 (en) | Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient | |
| US8859499B2 (en) | Method of enhancing efficacy of blood transfusions | |
| JP5037684B2 (ja) | ドセタキセル高分子誘導体、並びにその製造方法及びその用途 | |
| AU2024259730A1 (en) | IL-2 conjugates | |
| JP6463361B2 (ja) | 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート | |
| CN106714820A (zh) | 选择素及icam/vcam肽配体偶联物 | |
| JP6799823B2 (ja) | ポリ（ｌ−アルギニン）セグメント含有ブロック共重合体とポリアニオン性ポリマーのポリイオンコンプレックス | |
| JP2020526497A (ja) | 合成バイオコンジュゲート | |
| EP3068438A1 (en) | Relaxin prodrugs | |
| US20220289903A1 (en) | Polymer and composition from renewable source | |
| RU2012105579A (ru) | Способ конъюгирования полимера с белком, конъюгат, полученный указанным способом, композиция и лекарственное средство на его основе и способ лечения с их помощью | |
| JP2011162569A (ja) | カンプトテシン高分子誘導体及びその用途 | |
| JP6735759B2 (ja) | カンプトテシン類高分子誘導体を含有する医薬組成物 | |
| CN112424239B (zh) | 高分子化合物及使用了该高分子化合物的细胞内化合物导入促进剂 | |
| JP6797182B2 (ja) | カンプトテシン類高分子誘導体を含有する医薬製剤 | |
| RU2002102232A (ru) | Конъюгаты эритропоэтина и полиэтиленгликоля (второе название "Производные эритропоэтина") | |
| RU2015147544A (ru) | Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе | |
| AU2022258944A1 (en) | Compositions comprising cross-linked hyaluronic acid, and methods of use thereof | |
| JP2022129250A (ja) | ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160527 |